Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥2,000 JPY
Change Today -52.00 / -2.53%
Volume 142.7K
4569 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
As of 2:00 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

kyorin holdings inc (4569) Snapshot

Open
¥2,061
Previous Close
¥2,052
Day High
¥2,068
Day Low
¥1,986
52 Week High
03/12/15 - ¥3,040
52 Week Low
09/4/15 - ¥1,986
Market Cap
149.9B
Average Volume 10 Days
237.1K
EPS TTM
¥149.48
Shares Outstanding
74.9M
EX-Date
09/28/15
P/E TM
13.4x
Dividend
¥52.00
Dividend Yield
2.60%
Current Stock Chart for KYORIN HOLDINGS INC (4569)

Related News

No related news articles were found.

kyorin holdings inc (4569) Related Businessweek News

No Related Businessweek News Found

kyorin holdings inc (4569) Details

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical, generic, over-the-counter drugs, and others in Japan and internationally. The company operates in two segments, Pharmaceutical Business and Consumer Healthcare (Skincare) Business. Its products primarily include Flutiform, a drug for the treatment of asthma; Uritos, which is a therapeutic agent for overactive bladder; Kipres for the treatment of bronchial asthma and allergic rhinitis; Pentasa for the treatment of ulcerative colitis and Crohn’s disease; and Mucodyne, a mucoregulan drug. The company also offers Milton, a baby bottle disinfectant; Rubysta, a disinfectant cleaner; skincare and cosmetic products based on nanocapsule technology, a pharmaceutical formulation concept; and prescription medicines and quasi-drugs, diagnostics, and industrial chemicals. In addition, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies’ technologies and collection of information concerning clinical trials. Further, the company’s pipeline products include KRP-AB1102 and KRP-AB1102F for the treatment of chronic obstructive pulmonary disease that are under Phase III clinical development; KRP-AM1977X for the treatment of infectious diseases that is under Phase II clinical development; and KRP-114V and KRP-EPA605 for overactive bladder. Additionally, it pipeline products comprise KRP-209 for Tinnitus; KRP-203 for transplantation, autoimmune diseases, and IBD; KRP-AM1977X, an oral antibacterial agent; and KRP-AM1977Y, an injection. The company’s other pipeline products include Ad-SGE-REIC formulation, a gene-therapy product; and Dimethyl sulfoxide for the treatment of interstitial cystitis. KYORIN Holdings, Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

2,445 Employees
Last Reported Date: 06/24/15
Founded in 1923

kyorin holdings inc (4569) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyorin holdings inc (4569) Key Developments

Kyorin Holdings, Inc. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Provides Dividend Guidance for Second Quarter and Full Year of Fiscal Year Ending March 31, 2016; Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2016

KYORIN Holdings, Inc. announced consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported net sales of JPY 26,567 million compared with JPY 26,397 million for the same period a year ago. Operating income was JPY 2,173 million compared with JPY 3,575 million for the same period a year ago. Ordinary income was JPY 2,316 million compared with JPY 3,847 million for the same period a year ago. Net income was JPY 1,757 million or JPY 23.76 per share compared with JPY 2,681 million or JPY 35.88 per share for the same period a year ago. The company provided dividend guidance for second quarter and full year of fiscal year ending March 31, 2016. For the quarter, the company plans to pay an interim dividend of JPY 20.00 per share against JPY 20.00 per share paid a year ago. For the year, the company plans to pay final dividend of JPY 32.00 per share against JPY 32.00 per share paid a year ago. The company provided earnings guidance for the first half and full year of fiscal year ending March 31, 2016. For the first half, on consolidated basis, the company expects to report net sales of JPY 54,400 million, operating income of JPY 3,800 million, ordinary income of JPY 4,000 million and profit attributable to owners of parent of JPY 2,600 million or JPY 52.20 per share. For the full year, on consolidated basis, the company expects to report net sales of JPY 120,200 million, operating income of JPY 16,000 million, ordinary income of JPY 16,300 million and profit attributable to owners of parent of JPY 11,500 million or JPY 155.51 per share.

KYORIN Holdings, Inc. to Report Q1, 2016 Results on Jul 30, 2015

KYORIN Holdings, Inc. announced that they will report Q1, 2016 results on Jul 30, 2015

KYORIN Holdings, Inc., Annual General Meeting, Jun 23, 2015

KYORIN Holdings, Inc., Annual General Meeting, Jun 23, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4569:JP ¥2,000.00 JPY -52.00

4569 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4569.
View Industry Companies
 

Industry Analysis

4569

Industry Average

Valuation 4569 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYORIN HOLDINGS INC, please visit www.kyorin-gr.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.